The CNS can be a safe space for CARs

Abstract

In this issue of Blood, Frigault et al report that tisagenlecleucel, a CD19-specific chimeric antigen receptor (CAR) T-cell product, has a safety profile in a small series of patients with aggressive B-cell non-Hodgkin lymphomas (B-NHLs) and secondary central nervous system (CNS) involvement similar to that seen in patients without active CNS disease.1 The Frigault et al study suggests that this product may benefit this previously excluded group of patients without an increased risk of neurotoxicity.